Introduction: The Unpredictability of Life and Science
In a recent letter to the metastatic breast cancer (MBC) community, Dr. Kelly Shanahan, President of METAvivor, offered a poignant reflection on the duality of living with a terminal diagnosis. Drawing a parallel between the volatile weather patterns in her home of Lake Tahoe—where spring sunshine can vanish under a blanket of snow in mere hours—and the unpredictable trajectory of metastatic disease, Dr. Shanahan underscored the urgency of her organization’s mission. As METAvivor continues to navigate a challenging landscape of funding and scientific advancement, the call to action remains clear: the patient voice must be at the center of clinical research.
Main Facts: A Surge in Research Interest
The most significant indicator of the current state of metastasis research is the overwhelming response to METAvivor’s latest grant cycle. This year, the Scientific Advisory Board (SAB) received 200 letters of intent (LOIs), a figure that mirrors last year’s record-breaking numbers.
According to Dr. Stuart Martin, a long-standing member of the SAB, this volume of interest serves as a barometer for the broader scientific community. “METAvivor is doing outstanding work to help metastasis research keep moving forward during this especially challenging time for research,” Dr. Martin noted, acknowledging the current climate of uncertainty surrounding federal research funding.
The process is rigorous: these 200 LOIs are currently being vetted. Those deemed the most impactful will be invited to submit full applications, which will undergo a dual-review process involving both scientific experts and Patient Advocate Reviewers (PARs). METAvivor is actively seeking both researchers and patient advocates to join this vital review process, emphasizing that the bridge between the laboratory and the bedside is built by those who understand the lived experience of the disease.
Chronology: A Roadmap of Advocacy and Innovation
The coming weeks mark a critical period for metastatic breast cancer advocacy on the global stage.
- Late May (ASCO 2024): The focus shifts to Chicago for the American Society of Clinical Oncology (ASCO) annual meeting. Dr. Shanahan has been invited to deliver a featured presentation, "Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials." Her address, scheduled for May 31, centers on the necessity of designing trials that reflect what patients actually value.
- Mid-June (Global Cancer Consortium): Dr. Shanahan will travel to Minnesota for the Hormel Institute’s Global Cancer Consortium. Here, she will continue her advocacy work, urging researchers to "build a bigger table" that includes those living with MBC as primary stakeholders. Keynote speaker Dr. Danny Welch, a seminal figure in metastasis research and an SAB member, will join her in representing METAvivor’s commitment to scientific excellence.
- Ongoing (Regulatory Milestones): The regulatory landscape remains fluid. Recent deliberations by the FDA’s Oncologic Drugs Advisory Committee (ODAC) regarding camizestrant—a treatment for patients with ESR1 mutations—have sparked intense debate within the oncology community. While the FDA continues to review the data, the European Medicines Agency (EMA) has shown more optimistic movement, illustrating the complex, international nature of drug approval.
Supporting Data: Recent FDA Breakthroughs
Despite the hurdles in clinical trial design and funding, May 2024 has been a month of significant therapeutic progress. The FDA has greenlit several treatments that offer new hope for specific patient cohorts:
- Veppanu (vepdegestrant): Approved for the treatment of ER+, HER2- MBC in patients harboring an ESR1 mutation. This represents a targeted approach to a specific genetic driver of resistance.
- Datroway (datopotamab deruxtecan): Authorized as a first-line treatment for patients with metastatic Triple-Negative Breast Cancer (TNBC) who are ineligible for immunotherapy. This expands the options for one of the most aggressive forms of the disease.
- Enhertu (trastuzumab deruxtecan): The FDA expanded the indication for this therapeutic in the early-stage HER2+ setting, a strategic move aimed at reducing the risk of recurrence and preventing the development of metastatic disease in the first place.
These approvals represent a shift toward precision medicine, where therapy is tailored to the molecular signature of the tumor rather than a one-size-fits-all approach.
Official Responses and Implications
The primary implication of these developments is that the patient voice is no longer a peripheral concern; it is a necessary component of modern drug development. Dr. Shanahan’s upcoming talk at ASCO, which humorously references the Spice Girls to emphasize the importance of listening to patient needs, underscores a shift in how medical professionals approach clinical endpoints.
For years, clinical trials were judged primarily on progression-free survival (PFS) or overall survival (OS). Today, there is a mounting push to include "patient-centered endpoints"—measuring quality of life, symptom management, and the actual utility of a drug in the context of daily living.
The discussion surrounding camizestrant highlights the tension between regulatory caution and the desperate need for novel treatments. When the FDA decides whether to approve a switch to an investigational drug when a mutation is detected—even before imaging confirms disease progression—they are weighing the risks of toxicity against the potential to halt the disease’s evolution. This conversation, recently featured on the Live from Stage 4 podcast, serves as a critical educational resource for the patient community to understand the intricacies of regulatory decision-making.
Building a Community: The Role of Live from Stage 4
As the landscape of cancer treatment evolves, so too does the need for accessible, accurate information. The Live from Stage 4 podcast has emerged as a cornerstone of this effort. By providing "news for us, by us," the platform bridges the gap between complex oncological data and the real-world experiences of patients.
Recent episodes featuring board members Janice Cowden, Lynda Weatherby, and Dr. Shanahan have provided a deep dive into the ODAC process. The upcoming follow-up episodes, which will host oncologists to discuss how to integrate emerging technologies into regulatory pathways, signal a growing collaborative effort between clinicians and the patient population they serve.
Conclusion: A Call for Sustained Action
As Dr. Shanahan prepares for her own medical scans following the ASCO conference, her message remains one of grounded optimism. The progress being made in the laboratory is tangible, yet the dependency on individual donations remains the lifeblood of METAvivor’s research grants.
The path forward requires a three-pronged approach: consistent funding from a public that understands the lethality of metastatic disease, an unwavering commitment from researchers to include patient advocates in trial design, and a regulatory environment that balances safety with the urgent needs of those who cannot afford to wait.
For those looking to contribute to this mission, the path is clear: advocate for policy changes, participate as a reviewer in the grant process, and provide financial support where possible. As Dr. Shanahan concludes, the future of MBC research depends on the collective will of a community that refuses to be sidelined, demanding instead to be architects of the very science intended to save them.
For more information on how to support metastatic breast cancer research or to participate as a Patient Advocate Reviewer, please visit the official METAvivor website at metavivor.org.
About the Author
